=Edwards Lifesciences (EW) reported earnings on Tue 25 Oct 2016 (a/h)

Edwards Lifesciences reports EPS in-line, misses on revs; guides Q4 EPS in-line, revs below consensus  :

• Reports Q3 (Sep) earnings of $0.68 per share, in-line with the Capital IQ Consensus of $0.68; revenues rose 20.1% year/year to $739.4 mln vs the $749.07 mln Capital IQ Consensus.
• For the quarter, the company's gross profit margin was 72.8 percent, compared to 76.2 percent in the same period last year. This decrease, which was expected, was driven predominately by foreign exchange.
• Co issues guidance for Q4, sees EPS of $0.67-0.77 vs. $0.74 Capital IQ Consensus Estimate; sees Q4 revs of $750-790 mln vs. $801.51 mln Capital IQ Consensus Estimate.
• "As patients and clinicians increasingly prefer TAVR, we remain as optimistic as ever about the long-term growth opportunity. We are committed to aggressively investing in our future, consistent with our focused innovation strategy. We are confident these investments will result in innovative therapies that will enable us to treat a broader group of patients and drive continued strong organic growth."